Home › Research › Treatments
Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease
Tábuas-Pereira M, Moreira AP, Castelo-Branco M, Abrunhosa A, Santana I.. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026-11-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Anti-amyloid monoclonal antibodies are the first drugs approved as disease targeted therapies for the treatment of early Alzheimer's disease (AD). Donanemab and Lecanemab have shown a reduction of amyloid in amyloid PET scans, with an average of - 55.48 centiloids in the Lecanemab trial and - 88.0 centiloids in the Donanemab trial at 18 months. Despite their efficacy, these treatments are associated with amyloid-related imaging abnormalities (ARIA), necessitating regular MRI surveillance and strategies that minimize treatment duration to reduce risk. Economic modeling indicates that amyloid PET at 52 weeks is cost-effective when its cost is below 20.8-23.2% of the price of 78-week Donanemab therapy, translating into substantial savings and reduced adverse-event exposure. Studies with lecanemab are missing. Broader implementation is limited by access, cost, and the need for standardized centiloid quantification. Overall, amyloid PET appears to be a valuable tool for guiding duration-limited Donanemab therapy and may improve safety, efficiency, and resource utilization.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tábuas-Pereira, M., Moreira, A. P., Castelo-Branco, M., Abrunhosa, A., & Santana, I. (2026). Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. https://doi.org/10.1007/s10072-026-09535-x
Vancouver
Tábuas-Pereira M, Moreira AP, Castelo-Branco M, Abrunhosa A, Santana I. Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2026. doi:10.1007/s10072-026-09535-x. PMID: 42988979.
BibTeX
@article{tabuaspereira2026-42988979,
author = {Tábuas-Pereira, M. and Moreira, A. P. and Castelo-Branco, M. and Abrunhosa, A. and Santana, I.},
title = {{Amyloid PET is a cost-effective exam to monitor Donanemab treatment in Alzheimer's disease}},
journal = {Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology},
year = {2026},
doi = {10.1007/s10072-026-09535-x},
pmid = {42988979},
url = {https://doi.org/10.1007/s10072-026-09535-x}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Despite their efficacy, these treatments are associated with amyloid-related imaging abnormalities (ARIA), necessitating regular MRI surveillance and strategies that minimize treatment duration to reduce risk.
- Economic modeling indicates that amyloid PET at 52 weeks is cost-effective when its cost is below 20.8-23.2% of the price of 78-week Donanemab therapy, translating into substantial savings and reduced adverse-event exposure.
- Overall, amyloid PET appears to be a valuable tool for guiding duration-limited Donanemab therapy and may improve safety, efficiency, and resource utilization.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Effect size23.2%
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 27 of the 58 points we could judge it on, which is 47 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42988979) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 27 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 27 of the 58 points we could judge it on is 47 out of 100. |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “amyloid-pet”
2 studies in the library carry the topic tag “amyloid-pet”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.